Published Date: 26 Apr 2023
According to new research, patients can rest assured that postponing stoma reversal surgery has no impact on long-term results.
Read Full NewsAs part of NeurologyLive®'s Year in Review 2025, we've compiled some notable trials that began in 2025.
The director of the Pediatric Epilepsy Center at UCSF reviewed recently presented interim phase 1/2 data for ETX101, a one-time AAV9 gene regulation therapy aiming to increase SCN1A expression in inhibitory interneurons in Dravet syndrome.
As part of NeurologyLive®'s Year in Review, take a look at our top expert interviews regarding multiple sclerosis in 2025.
Hidradenitis Suppurativa in 2025: Year in Review
1.
Six breast texture patterns linked to higher risk of invasive cancer
2.
Renewing the call for a national Cancer Patient's Bill of Rights
3.
Limits to Anti-Nausea Pill Coverage Wear on Cancer Patients and Doctors
4.
For patients with clear cell renal cell carcinoma, a new PET agent allows for same-day imaging.
5.
A new drug delivery system may help patients with a rare eye cancer
1.
The New Frontier of Cancer Survivorship: Navigating the Long-Term Effects of Immunotherapy and Targeted Therapies
2.
Unraveling the Mysteries of Metastasis: Exploring the Latest Advances in Cancer Research
3.
Mastering Breast Cancer Care in 2025: Diagnosis, Treatment, Education, and Innovation
4.
Molecular Mechanisms, Clinical Efficacy, and Stem Cell Therapy Integration in Leukemia Treatment
5.
CEUS in Endometrial Cancer: A Tool for Early Myometrial Infiltration Detection
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
2.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
3.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
5.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation